802-803 / 2605
‹#›
Strategies of RTOG-1308:
a)
The prescribed dose for this study is 70 Gy. The study is
designed to allow lower doses in situations for which critical
structure constraints cannot be met. After randomization the
patient’s dose will be individualized to the highest achievable dose
(within normal tissue organs-at-risk constraints) between 60-70
Gy;
b)
Cross-over from protons to photons not permitted.
c)
The protocol will maintain strict organs-at-risk constraints for
this trial;
d)
The protocol will perform preliminary quality assurance review
as patients are entered on the trial to monitor dose prescriptions
and dose/contouring compliance.